Pulse Biosciences, Inc. (PLSE) Financial Analysis & Valuation | Quarter Chart

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue t... more
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$3.68BExchangeNASDAQ
SectorHealthcareIndustryMedical - Instruments & Supplies
CountryUSCEOPaul Arthur LaViolette
IPO Date2016-05-18CAGR
Employees116Websitewww.pulsebiosciences.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
PLSE chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$2.53BP/E-45.01Forward P/E-46.05PEG
P/S48377.72P/B576.02P/CF-757.41P/FCF-753.71
Sales$1.19MSales 1Yinf%Sales 3Y-13266.67%Sales 5Yinf%
EPS$-1.18EPS 1Y9.35%EPS 3Y-4.88%EPS 5Y-50%
Sales QoQ8.23%EPS QoQ38.46%Sales QoQ AvgEPS QoQ Avg7.92%
Gross Margin-21.6%Operating Margin-7007.76%Profit Margin-6755.78%ROCE-79.4%
ROA-69%ROE-94%Altman Z Score117.62Piotroski Score3
Current Ratio9.63Quick Ratio9.61Cash Ratio9.26Op. CF Ratio-3.03
Debt/Equity0.07Debt/Assets0.06Lt Debt/Equity0.05Lt Debt/Cap.0.05
Intrst Cov.Inventory Turnover6.11Asset Turnover0.01Receivables Turnover9.71
Enterprise Value$2.53BP/E Ratio-45.01
Forward P/E-46.05PEG Ratio
P/S Ratio48377.72P/B Ratio576.02
P/CF Ratio-757.41P/FCF Ratio-753.71
EPS$-1.18EPS Growth 1Y9.35%
EPS Growth 3Y-4.88%EPS Growth 5Y-50%
Revenue Growth 1Yinf%Gross Margin-0.22%
Operating Margin-70.08%Profit Margin-67.56%
ROE-0.94%ROA-0.69%
ROCE-0.79%Current Ratio9.63
Quick Ratio9.61Cash Ratio9.26
Debt/Equity0.07Interest Coverage
Altman Z Score117.62Piotroski Score3

Pulse Biosciences, Inc. (PLSE) valuation & financials

Pulse Biosciences, Inc. (PLSE) has a market capitalization of $3.68B and trades at a price-to-earnings ratio of -45.0. It operates in the Healthcare sector (Medical - Instruments & Supplies).

Pulse Biosciences, Inc.'s revenue grew +inf% over the last year.

Pulse Biosciences, Inc.'s next earnings report is scheduled for November 4, 2026 after market close; analysts estimate EPS of $-0.35. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate PLSE EPS of $-0.35 for the upcoming quarter. See Pulse Biosciences, Inc. revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Pulse Biosciences, Inc. (PLSE) — frequently asked questions

When does Pulse Biosciences, Inc. (PLSE) report earnings next?

Pulse Biosciences, Inc. is expected to report earnings on November 4, 2026 after market close. Analysts estimate EPS of $-0.35.

What is Pulse Biosciences, Inc.'s market cap?

Pulse Biosciences, Inc. (PLSE) has a market capitalization of $3.68B.

What is PLSE's P/E ratio?

Pulse Biosciences, Inc. trades at a price-to-earnings ratio of -45.0, with trailing twelve-month EPS of $-1.18.

How fast is Pulse Biosciences, Inc. growing?

Pulse Biosciences, Inc.'s revenue grew +inf% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)